-
Something wrong with this record ?
Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases
K. Němejcová, J. Rosmusová, M. Bártů, M. Důra, I. Tichá, P. Dundr,
Language English Country United States
Document type Journal Article
- MeSH
- Adenocarcinoma, Clear Cell diagnosis pathology MeSH
- Biopsy MeSH
- Diagnosis, Differential MeSH
- Adult MeSH
- Endometrium pathology MeSH
- Carcinoma, Endometrioid diagnosis pathology MeSH
- Endometrial Hyperplasia diagnosis pathology MeSH
- Immunohistochemistry MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Biomarkers, Tumor metabolism MeSH
- Endometrial Neoplasms diagnosis pathology MeSH
- Polyps diagnosis pathology MeSH
- Precancerous Conditions diagnosis pathology MeSH
- Glucose Transporter Type 1 metabolism MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Glucose transporter-1 (Glut-1) is a membrane glycoprotein that is, together with other glucose transporters, responsible for the regulation of glucose uptake. An increased expression of this protein seems to be a general feature of several malignant tumors that are able to reprogram their metabolism and switch from oxidative phosphorylation to aerobic glycolysis. METHODS: We performed comprehensive immunohistochemical analysis of Glut-1 expression in 336 endometrial samples, including tumors, nontumor lesions, and normal tissues. RESULTS: Expression of Glut-1 was found in 87% of endometrioid carcinomas (160/184 cases), 100% of serous carcinomas (29/29 cases), 100% of clear cell carcinomas (17/17 cases), 50% of polyps with atypical hyperplasia (8/16 cases), 12.5% of polyps with non-atypical hyperplasia (3/24 cases), 77% of hyperplasias with atypias (10/13 cases), 9% of hyperplasias without atypias (1/11 cases), 87% of secretory endometrium samples (13/15 cases), and in none of the nonsecretory endometrium samples (0/27 cases). In endometrioid carcinomas, Glut-1 was expressed in a marked geographical pattern. In nontumor lesions, its expression was more common in atypical hyperplasia and polyps with atypical hyperplasia compared with polyps with non-atypical hyperplasia and hyperplasias without atypia ( P = .00032). CONCLUSION: Our study confirms the high expression of Glut-1 not only in endometrioid carcinomas but also in other carcinomas of endometrium including clear cell and serous types. Glut-1 expression can be used as a surrogate marker in differential diagnosis between hyperplasia with and without atypia. Because of common Glut-1 expression in malignant tumors, therapeutic strategies influencing this protein or its signaling pathways can be beneficial.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025103
- 003
- CZ-PrNML
- 005
- 20180712120243.0
- 007
- ta
- 008
- 180709s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/1066896916683510 $2 doi
- 035 __
- $a (PubMed)28381136
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Němejcová, Kristýna $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 245 10
- $a Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases / $c K. Němejcová, J. Rosmusová, M. Bártů, M. Důra, I. Tichá, P. Dundr,
- 520 9_
- $a BACKGROUND: Glucose transporter-1 (Glut-1) is a membrane glycoprotein that is, together with other glucose transporters, responsible for the regulation of glucose uptake. An increased expression of this protein seems to be a general feature of several malignant tumors that are able to reprogram their metabolism and switch from oxidative phosphorylation to aerobic glycolysis. METHODS: We performed comprehensive immunohistochemical analysis of Glut-1 expression in 336 endometrial samples, including tumors, nontumor lesions, and normal tissues. RESULTS: Expression of Glut-1 was found in 87% of endometrioid carcinomas (160/184 cases), 100% of serous carcinomas (29/29 cases), 100% of clear cell carcinomas (17/17 cases), 50% of polyps with atypical hyperplasia (8/16 cases), 12.5% of polyps with non-atypical hyperplasia (3/24 cases), 77% of hyperplasias with atypias (10/13 cases), 9% of hyperplasias without atypias (1/11 cases), 87% of secretory endometrium samples (13/15 cases), and in none of the nonsecretory endometrium samples (0/27 cases). In endometrioid carcinomas, Glut-1 was expressed in a marked geographical pattern. In nontumor lesions, its expression was more common in atypical hyperplasia and polyps with atypical hyperplasia compared with polyps with non-atypical hyperplasia and hyperplasias without atypia ( P = .00032). CONCLUSION: Our study confirms the high expression of Glut-1 not only in endometrioid carcinomas but also in other carcinomas of endometrium including clear cell and serous types. Glut-1 expression can be used as a surrogate marker in differential diagnosis between hyperplasia with and without atypia. Because of common Glut-1 expression in malignant tumors, therapeutic strategies influencing this protein or its signaling pathways can be beneficial.
- 650 _2
- $a adenokarcinom z jasných buněk $x diagnóza $x patologie $7 D018262
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a endometroidní karcinom $x diagnóza $x patologie $7 D018269
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a hyperplazie endometria $x diagnóza $x patologie $7 D004714
- 650 _2
- $a nádory endometria $x diagnóza $x patologie $7 D016889
- 650 _2
- $a endometrium $x patologie $7 D004717
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a přenašeč glukosy typ 1 $x metabolismus $7 D051272
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a polypy $x diagnóza $x patologie $7 D011127
- 650 _2
- $a prekancerózy $x diagnóza $x patologie $7 D011230
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rosmusová, Jana $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Bártů, Michaela $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Důra, Miroslav $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. 2 Department of Dermatovenerology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Tichá, Ivana $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Dundr, Pavel $u 1 Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00002376 $t International journal of surgical pathology $x 1940-2465 $g Roč. 25, č. 5 (2017), s. 389-396
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28381136 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712120536 $b ABA008
- 999 __
- $a ok $b bmc $g 1317234 $s 1022024
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 25 $c 5 $d 389-396 $e 20161218 $i 1940-2465 $m International journal of surgical pathology $n Int. j. surg. pathol. $x MED00002376
- LZP __
- $a Pubmed-20180709